Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design.

Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects. Cardiovasc Ultrasound (2005) 1.34

Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease. Heart Fail Clin (2012) 0.87

Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure. Clin Interv Aging (2010) 0.81

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J (2012) 16.00

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J (2008) 12.32

Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med (2005) 12.03

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med (2012) 9.22

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75

Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55

A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32

Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25

Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation (2008) 7.11

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail (2008) 6.80

Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2007) 6.34

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J (2013) 6.17

Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA (2007) 6.06

Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00

Effusive-constrictive pericarditis. N Engl J Med (2004) 5.82

Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J (2013) 5.23

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81

The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol (2013) 4.81

EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57

Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation (2002) 4.56

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49

Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet (2013) 4.39

Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ (2006) 4.18

Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14

Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A (2005) 4.13

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10

Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation (2012) 4.09

Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med (2006) 4.07

Increased metaboreceptor stimulation explains the exaggerated exercise pressor reflex seen in heart failure. J Appl Physiol (1985) (2007) 4.02

Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90

Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation (2003) 3.89

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J (2016) 3.83

Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation (2003) 3.75

2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J (2015) 3.70

Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol (2012) 3.56

Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J (2006) 3.55

Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med (2005) 3.52

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2013) 3.50

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood (2006) 3.49

Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 3.48

Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J (2004) 3.45

Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol (2002) 3.45

Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet (2008) 3.36

State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34

Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int (2011) 3.32

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J (2004) 3.27

Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14

Update on myocarditis. J Am Coll Cardiol (2012) 3.12

Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol (2007) 3.09

Ethical authorship and publishing. Int J Cardiol (2008) 2.97

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2016) 2.91

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA (2007) 2.90

Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90

Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88

Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. Eur Heart J (2004) 2.87

Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87

Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: oxygen uptake efficiency slope. Eur Heart J (2005) 2.84

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet (2010) 2.75

Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA (2005) 2.74